S

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990

Watchlist Manager
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Watchlist
Price: 172.5 HKD -3.42% Market Closed
Market Cap: 38.4B HKD
Have any thoughts about
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd?
Write Note

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Operating Expenses
-ÂĄ1.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Operating Expenses
-ÂĄ23.5B
CAGR 3-Years
-22%
CAGR 5-Years
-32%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Operating Expenses
-ÂĄ7.2B
CAGR 3-Years
-10%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Operating Expenses
-ÂĄ3.1B
CAGR 3-Years
-41%
CAGR 5-Years
-42%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Operating Expenses
-ÂĄ4.9B
CAGR 3-Years
-29%
CAGR 5-Years
-28%
CAGR 10-Years
-30%
Imeik Technology Development Co Ltd
SZSE:300896
Operating Expenses
-ÂĄ649m
CAGR 3-Years
-53%
CAGR 5-Years
-35%
CAGR 10-Years
N/A
No Stocks Found

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
Glance View

Market Cap
38.4B HKD
Industry
Biotechnology

Nestled in the vibrant economic landscape of China, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. emerges as a prominent figure within the biopharmaceutical industry. Founded as a subsidiary of the larger pharmaceutical umbrella of Sichuan Kelun Pharmaceutical Co., Ltd., the company leverages its parent's extensive network and expertise to carve its niche in an ever-evolving market. Kelun-Biotech focuses on innovation in drug development, particularly in biologics and complex generics. This focus allows it to produce high-value pharmaceuticals that address urgent medical needs, spanning across treatments for oncology, immunological disorders, and other critical health segments. Its dedication to cutting-edge research and development is evident in the substantial investments it channels into its laboratories and collaborations with leading research institutions, both domestically and internationally. The company's revenue model pivots around the commercialization of its proprietary drugs and partnerships with multinational pharmaceutical firms, where it contributes its research prowess to joint ventures. By positioning itself as a leader in the biologics sector, Kelun-Biotech capitalizes on the growing demand for biosimilars and innovative therapies in the global market. Its strategy to penetrate international markets is further bolstered by strategic alliances and compliance with stringent global regulatory approvals, enhancing its credibility and reach. These endeavors not only drive its revenue growth but also reinforce its mission to deliver high-quality, affordable healthcare solutions worldwide, making Kelun-Biotech an influential player in addressing global health challenges through pharmaceutical excellence.

Intrinsic Value
102.03 HKD
Overvaluation 41%
Intrinsic Value
Price
S

See Also

What is Sichuan Kelun-Biotech Biopharmaceutical Co Ltd's Operating Expenses?
Operating Expenses
-1.2B CNY

Based on the financial report for Dec 31, 2023, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd's Operating Expenses amounts to -1.2B CNY.

What is Sichuan Kelun-Biotech Biopharmaceutical Co Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 1Y
-33%

Over the last year, the Operating Expenses growth was -33%.

Back to Top